60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) Stock Short Interest Jumps 88.4%

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP – Get Free Report) saw a significant increase in short interest in October. As of October 30th, there was short interest totaling 255,088 shares, an increase of 88.4% from the October 15th total of 135,408 shares. Approximately 7.4% of the company’s shares are short sold. Based on an average daily volume of 1,664,816 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Monday, September 21st. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $13.85.

Get Our Latest Analysis on 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Stock Up 0.8%

SXTP traded up $0.00 during trading hours on Tuesday, hitting $0.50. 11,729 shares of the company’s stock were exchanged, compared to its average volume of 1,430,460. The stock has a market cap of $1.75 million, a price-to-earnings ratio of -0.10 and a beta of 2.47. 60 Degrees Pharmaceuticals has a 1-year low of $0.46 and a 1-year high of $8.62. The stock’s 50-day moving average is $0.93 and its two-hundred day moving average is $1.63.

60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) last issued its quarterly earnings results on Monday, November 16th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.27 million. On average, equities research analysts anticipate that 60 Degrees Pharmaceuticals will post -3.31 EPS for the current year.

About 60 Degrees Pharmaceuticals

(Get Free Report)

60 Degrees Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for infectious diseases, particularly malaria and other parasitic infections. Its portfolio includes tafenoquine, an antimalarial medicine marketed in the United States as ARAKODA for the prevention of malaria in adults. The company is also studying tafenoquine for potential use against babesiosis, a tick-borne parasitic disease. These development programs are investigational; tafenoquine’s approval for malaria prevention does not extend to babesiosis.

See Also

Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.